Skip to Content

Research & Funding

Past Other NCI & NIH InitiativesRSS

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • Non-Invasive Methods for Diagnosis and Progression of Diabetes, Kidney, Urological, Hematological and Digestive Diseases (R01) (NIDDK) (PA-09-181)

    • Release Date: May 01, 2009
    • Application Receipt Date: Standard dates apply
    • Expiration Date: May 8, 2012
    • Contacts:

      Maren R Laughlin, Ph.D., NIDDK, Phone: 301-594-8802, Email: ml33g@nih.gov

    This Funding Opportunity Announcement (FOA) is a call for the application of imaging and other non- or minimally-invasive technologies to detect, characterize, diagnose, identify persons with predisposition to, or monitor treatment of diseases of interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Also needed are new, robust surrogate markers for clinical trial endpoints, and new ways to characterize normal and pathological tissues in vivo. Diseases of interest include type 1 and 2 diabetes; acute and chronic kidney disease, liver, urologic, hematologic, digestive, endocrine, and metabolic diseases and their complications; obesity; obesity-related hypertension, hypertension, renal and vascular disorders leading to hypertension. Applicable techniques include molecular imaging and functional imaging approaches, imaging methods with high spatial, chemical or time resolution, metabolomics, proteomics, genomics, or new spectroscopic or sensor array technologies for monitoring metabolic or physiological events.

    URL: http://grants.nih.gov/grants/guide/pa-files/PA-09-181.html

  • PAR-09-129: Solicitation of assays for high throughput screening (HTS) in the molecular libraries screening centers network (MLPCN)(R03)

    • Release Date: March 12, 2009
    • Application Receipt Date: See below
    • Expiration Date: January 5, 2012
    • Contacts:

      Yong Yao, Ph.D., NIH Roadmap Molecular Libraries and Imaging, Phone: (301) 443-6102, Email: yyao@mail.nih.gov

    • Letters of Intent Receipt Date(s): Letters of Intent Receipt Date(s): Apr. 13, 2009; Aug. 4, 2009; Dec. 4. 2009; Apr. 4, 2010; Aug. 3, 2010; Dec. 4, 2010; Apr. 4, 2011; Aug. 2, 2011; and Dec. 4, 2011.
    • Application Submission Date(s):May 13, 2009; Sept. 4, 2009; Jan. 4. 2010; May 4, 2010; Sept. 3, 2010; Jan. 4, 2011; May 4, 2011; Sept. 2, 2011; and Jan. 4, 2012.

    The NIH Molecular Libraries Roadmap Initiative wishes to solicit HTS assay applications from investigators who have the interest and capability to work with the Molecular Libraries Probe Production Centers Network (MLPCN) in support of chemical probe development. This FOA promotes discovery and development of new chemical probes as research tools for use by scientists in both the public and private sector to advance the understanding of biological functions and disease mechanisms.

    See full description in NIH Guide:PAR-09-129

  • PAR-09-089: The NCI Transition Career Development Award (K22)

    • Release Date: January 23, 2009
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 8, 2012
    • Contacts:

      Sonia Jakowlew, Ph.D., Phone: 301-496-8580, Email: jakowles@mail.nih.gov

    The major objective of the NCI Transition Career Development Award program is two-fold: (i) to provide a mechanism for stabilizing the career tracks of the most promising of investigators while they are establishing their first independent research programs and (ii) to create equal access to extramural career development opportunities to postdoctoral scientists in basic human cancer research working as Federal employees.

    See full description in NIH Guide:PAR-09-089

  • PAR-09-088: Established Investigator Award in Cancer Prevention & Control (K05)

    • Release Date: January 22, 2009
    • Application Receipt Date: Standard dates apply for K award
    • Expiration Date: January 8, 2012
    • Contacts:

      Shannon M. Lemrow, Ph.D., NCI, Phone: 301-496-8580, Email: lemrows@mail.nih.gov

    The objective of the NCI Established Investigator Award in Cancer Prevention and Control (K05) is to provide qualified researchers with protected time to devote to research and mentoring. The award is designed for established scientists who have already demonstrated a sustained, high level of research and mentoring productivity and who need K05 support to continue these activities. The K05 award will provide salary support of 25 to 50 percent of the institutional base salary (up to the current Federal salary cap limit) for three to five years based on a full-time, 12-month staff appointment, plus fringe benefits. The award requires the candidate to devote a minimum of 25 percent of full-time professional effort towards conducting the experimental research plan and the mentoring activities described in the application. The award also provides $25,000 per year in research-related expenses. It is renewable for one additional 5-year period.

    See full description in NIH Guide:PAR-09-088

  • PA-09-043: Mentored Patient-Oriented Research Career Development Award (K23)

    The goal of the Mentored Patient-Oriented Research Career Development Award (K23) program is to ensure a future cadre of well-trained scientists working in POR areas who will become competitive for NIH research project (R01) grant support. The specific objectives of the Mentored Patient-Oriented Research Career Development Award are to:

    1)encourage research-oriented clinicians to develop independent research skills and gain experience in advanced methods and experimental approaches needed to become an independent investigator conducting patient-oriented research; 2) increase the pool of clinical researchers who can conduct patient-oriented studies, capitalizing on the discoveries of biomedical research and translating them to clinical settings; 3) support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research.

    For the purposes of this award, Patient-Oriented Research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. This area of research includes: 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials, and; 4) the development of new technologies. Studies falling under Exemption 4 for human subjects research are not included in this definition.

    See full description in NIH Guide:PA-09-043

  • PA-09-042: Mentored Clinical Scientist Research Career Development Award (K08)

    • Release Date: December 11, 2008
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: January 8, 2012
    • Contacts:

      Dorkina Myrick, M.D., Ph.D. (NCI), Phone: 301-496-8580, Email: Myrick@mail.nih.gov

    The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (K23).

    An award provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (http://grants.nih.gov/grants/guide/contacts/PA-09-042_contacts.html).

    See full description in NIH Guide:PAR-09-042

  • PA-09-004 & PA-09-005: Understanding the effects of emerging cellular, molecular, and genomic technologies on cancer health care delivery (R01) & (R21) (NCI)

    • Release Date: October 06, 2008
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 8, 2012
    • Contacts:

      Andrew Freedman, Ph.D., NCI, Phone: 301-435-6819, Email: freedmaa@mail.nih.gov

    The purpose is to invite applications for health services research addressing utilization of emerging cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.

    See full description in NIH Guide: R01 PA-09-004; R21 PA-09-005

  • PAR-08-120: Cancer Education Grants Program (R25)

    • Release Date: March 28, 2008
    • Application Receipt Date: Standard dates apply
    • Expiration Date: September 8, 2011
    • Contacts:

      Lester Gorelic, Ph.D., Tel: (301) 496-8580; Email: gorelicl@mail.nih.gov

    This Funding Opportunity Announcement (FOA) uses the NIH Research Education (R25) grant mechanism to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).

    Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

    The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to $300,000 per year.

    See full description in NIH Guide:PAR-08-120

  • PA-08-098: Functional Links between the Immune System, Brain Function and Behavior (R21)

    • Release Date: March 04, 2008
    • Application Receipt Date: Standard dates
    • Expiration Date: May 17, 2011
    • Contacts:

      Paige McDonald, Ph.D., MPH, Phone: 301-435-5037, Email: mcdonalp@mail.nih.gov

    The potent effects of neuroimmune molecules in the brain are mediated through multiple signaling pathways. However, details regarding the extent, routes, or mechanisms whereby immune signaling affects the brain in either normal conditions or during immune challenge and inflammation are largely unexplored. The purpose of this FOA is to identify research opportunities that may help to bridge the gap in understanding how immune cells and their mediators affect brain development, function and behaviors related to cognition and mood.

    See full description in NIH Guide:PA-08-098

  • Nanoscience and Nanotechnology in Biology and Medicine (R01: PAR-08-052); (R21: PAR-08-053)

    • Release Date: December 18, 2007
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 8, 2011
    • Contacts:

      Piotr Grodzinski grodzinp@mail.nih.gov

    This funding opportunity (FOA) is aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1 - 100 nanometers, where novel properties and functions occur because of the size. The National Cancer Institute (NCI) is interested in: 1. Early detection of the disease using imaging, 2. In vitro early diagnostics: multiplexed sensitive and specific sensors, 3. Multi-functional therapeutics and localized therapy delivery, and 4. Tools and approaches to interrogate, understand, and manipulate single cells, structures , and molecules.

    URLs:
    http://grants.nih.gov/grants/guide/pa-files/PAR-08-052.html (R01)
    http://grants.nih.gov/grants/guide/pa-files/PAR-08.053.html (R21)